Mark Rothera, Silence Therapeutics CEO

With first hu­man da­ta, long-strug­gling Si­lence Ther­a­peu­tics leaps in­to next big car­dio­vas­cu­lar race

Drug com­pa­nies have spent the last 40-plus years search­ing for in­creas­ing­ly high-tech ways of low­er­ing bad cho­les­terol in hopes of curb­ing heart dis­ease, still the lead­ing cause of death world­wide.

There are po­ten­tial­ly oth­er ways of curb­ing heart dis­ease for mil­lions, how­ev­er. For ex­am­ple, a fat-trans­port mol­e­cule called lipopro­tein a, or lp(a), ap­pears to in­crease heart dis­ease risk for 20% to 30% of the world pop­u­la­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.